Form 4: Fulcrum Therapeutics Director Kate Haviland Acquires 30,000 Stock Options

Director Kate Haviland reports acquisition of 30,000 stock options in Fulcrum Therapeutics, Inc.

Summary

• Kate Haviland, a director of Fulcrum Therapeutics, Inc., filed a Form 4 on June 18, 2024.
• The report details the acquisition of 30,000 stock options on June 17, 2024, at an exercise price of $7.
• These options vest on the first anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service, and expire on June 16, 2034.
• Following the transaction, Haviland directly owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which can be seen as a positive sign of alignment between management and shareholders, but doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of securities by a director of Fulcrum Therapeutics.

Stakeholder Impact

• Shareholders may view the stock option grant as a sign of confidence from the director in the company's future performance.

Key Dates